Emerging Role of Vaccines in Breast Cancer
DOI:
https://doi.org/10.61173/9ns5sn82Keywords:
Breast cancer, preventive vaccine, therapeutic vaccineAbstract
Breast cancer is a serious threat to women’s health. It can metastasize to vital organs, causing complications and endangering lives. Early detection and treatment can prolong survival. Although existing treatments such as chemotherapy, targeted therapy, and endocrine therapy have improved the overall cure rate of breast cancer, they are ineffective for patients with advanced metastatic breast cancer. Tumor vaccine therapy is expected to solve this problem by inducing the activation of the body’s immune system, precisely killing cancer cells, and reducing the chance of cancer recurrence. There are two types of breast cancer vaccines: preventive vaccines and therapeutic vaccines. Preventive vaccines are designed to activate the immune system in high-risk individuals, targeting specific antigens commonly found on breast cancer cells. Several ongoing clinical trials are testing these vaccines. Therapeutic vaccines are designed to treat patients already diagnosed with breast cancer by activating their immune system to recognize and attack cancer cells. Examples of therapeutic vaccines include peptide-based vaccines, whole-cell lysate vaccines, viral or DNA-based vaccines, and dendritic cell vaccines. This review introduces the types, mechanisms, and ongoing clinical trials of breast cancer vaccines, including preventive and therapeutic vaccines, and discusses the future research directions in this field.References
[1] Brown, Tommy A, et al. “Prospective, Randomized, Single- Blinded, Multi-Center Phase II Trial of Two HER2 Peptide Vaccines, GP2 and AE37, in Breast Cancer Patients to Prevent Recurrence.” Breast Cancer Research and Treatment, U.S. National Library of Medicine, June 2020, www.ncbi.nlm.nih. gov/pmc/articles/PMC7188712/.
[2] Mercogliano, María Florencia, et al. “Emerging Targeted Therapies for HER2-Positive Breast Cancer.” Cancers, U.S. National Library of Medicine, 26 Mar. 2023, www.ncbi.nlm.nih. gov/pmc/articles/PMC10093019/.
[3] Tobias, J, et al. “Vaccination against HER-2/Neu, with Focus on Peptide-Based Vaccines.” ESMO Open, U.S. National Library of Medicine, Feb. 2022, www.ncbi.nlm.nih.gov/pmc/ articles/PMC8760406/.
[4] Mittendorf, Elizabeth A, et al. “The E75 HER2/Neu Peptide Vaccine.” Cancer Immunology, Immunotherapy : CII, U.S. National Library of Medicine, Oct. 2008, www.ncbi.nlm.nih. gov/pmc/articles/PMC11029853/.
[5] Disis, Mary L Nora, et al. “Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients with Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial.” JAMA Oncology, U.S. National Library of Medicine, 1 Jan. 2023, www.ncbi.nlm.nih. gov/pmc/articles/PMC9634596/.
[6] Nava, Sara, et al. “Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.” International Journal of Molecular Sciences, U.S. National Library of Medicine, 15 Nov. 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8620771/.
[7] Lee, Kyu-Won, et al. “Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations.” Cells, U.S. National Library of Medicine, 25 Aug. 2023, www.ncbi.nlm.nih. gov/pmc/articles/PMC10486560/.
[8] Cintolo, Jessica A, et al. “Dendritic Cell-Based Vaccines: Barriers and Opportunities.” Future Oncology (London, England), U.S. National Library of Medicine, Oct. 2012, www. ncbi.nlm.nih.gov/pmc/articles/PMC4260651/.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
